Start main content

Endosomal Acidification Inhibitors for Influenza Virus and Coronavirus Treatment

Endosomal Acidification Inhibitors for Influenza Virus and Coronavirus Treatment
Therapeutic Biologics

Key Problem and Market Opportunity

  • Influenza viruses and SARS-CoV-2 which lead to seasonal outbreaks and a pandemic respectively have consistently overwhelmed healthcare institutions. The emergence of drug resistant viruses in patients while on treatment with specific anti-influenza drugs has fueled the development of alternative therapeutic strategies. The challenge is to identify a therapy which could inhibit the viral replication while preventing the generation of drug resistant viral variants upon intervention.
  • According to Global data, the therapeutic drugs market for COVID-19 is expected to increase, generating a total sales of $50.9B from 2020 to 2027. As for the global influenza market, it is estimated to reach nearly $6.5 billion by 2022, growing at a compound annual growth rate (CAGR) of 3.0% for the period of 2017 through 2022.

Key Advantages of the Technology

Technology Section Slider 1
Technology Section Slider 2
Technology Section Slider 3

Using endosomal acidification inhibitors (Chloroquine and P16 peptide), the inventors successfully inhibit SARS-CoV-2, SARS-CoV and Influenza virus replication in vivo through intranasal administration when lung cells could be bathed in chloroquine with effective concentration.


  • Increased bio-safety (no significant hemolysis was observed in turkey red blood cells upon treatment)
  • Significantly inhibit viral replication when the viruses were pretreated before viral infection
  • Does not induce drug resistant gene in virus upon treatment

Potential Product and Services

Anti-viral therapy for SAR-CoV-2 and Influenza virus

Development Status and IP Strength

Stage of Development
  • Chloroquine and P16 peptide have been tested in laboratory animals for its efficacy, safety and potency
  • US Provisional Application No. 63/150,110
  • US Provisional Application No. 63/150,141
IP Status
  • Patent application submitted

Work with us